Perrigo (NASDAQ:PRGO) Broadens its International Presence by Acquiring Rosemont; $283 Million Pact – PRGO, TEVA, VRX, NVS

Perrigo Company (NASDAQ:PRGO) purchased United Kingdom based Rosemont Pharmaceuticals Ltd, a specialty and generic prescription pharmaceutical firm, for almost GBP180 million or $283 million in a pact that broadens the company’s international presence and complements its United Kingdom over-the-counter business.

The store-brand pharmaceutical and nutritional-products maker, Rosemont, concentrates on oral liquid medicines and has a portfolio of over 90 products. The corporation booked revenue of GBP40 million for fiscal year 2012.

Perrigo projects the Rosemont acquisition will add almost 8 cents per share to its earnings for the remaining period of fiscal year.

Perrigo also forecasts the Rosemont purchase to add 24 cents per share to adjusted earnings in the first year after the agreement.

Shifting reader’s focus to broader market, let us consider market performance of other stocks that significantly affect same sector. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) fell -0.34% to settle at $38.55, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) moved down -0.35% to end at $67.56 while Novartis AG (ADR) (NYSE:NVS) dropped -0.04% to finish at $68.27 on Monday.

Perrigo Company (NASDAQ:PRGO) last session’s volume of 1.35 million shares was higher than its average volume of 868,202 shares. The stock after opening at $109.50 hit high price of $111.89 and then closed at $111.40 by scoring +2.86%.

PRGO generated revenue of $3.26 billion in the previous twelve months and earned $434.31 million. The Company showed a positive 13.31% in the net profit margin as well as in its operating margin which remained at 19.23%. Company’s annual sales growth for the past five years was 18.33%.

The PRGO’s past twelve months’ price to sales ratio was 5.34 and price to cash ratio remained 22.79. As far as the returns are concerned, PRGO’s return on equity was recorded as 23.25% and return on investment increased 12.53% while its return on asset stayed at 10.55%.

The stock showed weekly upbeat performance of 5.34% which was maintained for the month at 1.06%. Likewise the positive performance for the quarter was recorded as 6.00% and for the year was 18.95% while the YTD performance remained at 7.08%.

DO NOT TRADE ANY STOCK WITHOUT LEVEL 2 STOCK QUOTES! delivers it's user with the most in-depth Level 2 Quotation System available on the Planet! NO Downloads, NO Widgets, NO Plugins required! Stay on TOP of your trades with! CLICK HERE TO START YOUR FREE 30-DAY TRIAL

This entry was posted in Healthcare, Latest Headlines and tagged , , , , , , , , , , . Bookmark the permalink.